Kojin Therapeutics


kojin health logo

Vision

Kojin’s mission is to transform the future of medicine by harnessing groundbreaking discoveries in cell state and ferroptosis biology to create novel therapies and cures for diseases traditionally considered intractable.

Approach

Kojin Therapeutics is the first biopharmaceutical company using a proprietary approach to cell state and ferroptosis biology to develop novel therapeutics for diseases of high unmet need. The company is accelerating a drug discovery platform that connects complex cell states to known biochemical processes such as ferroptosis, or iron-dependent cell death, and enables development of selective therapies for a broad range of intractable diseases. By utilizing a novel non-genetic classification of cell states instead of conventional cell types, Kojin’s platform identifies specific targets for therapeutic intervention to develop medicines tailored to each disease that selectively target affected tissues.

Kojin Therapeutics is addressing

CEO:

Luba Greenwood

Founders:

Stuart Schreiber

Benjamin Cravatt

Stephanie Dougan

Vasanthi Viswanathan

First investment:

January 2020